back to US directory
us clinical guidance

Hepatitis B screening and test interpretation

CDC universal adult triple-panel screening, pregnancy and risk-based testing, result interpretation and linkage to liver care.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults needing one-time universal HBV screening, pregnant patients, people with ongoing risk and patients with an unexpected hepatitis B result. Pediatric risk-based testing, acute liver failure, antiviral selection and hepatocellular-carcinoma surveillance intervals require separate guidance. Screening, diagnostic testing, vaccination and treatment decisions are related but not interchangeable.
sources for this section:CDC HBV 2023

The Bottom Line

  • CDC recommends one-time hepatitis B screening for every adult aged 18 years or older using HBsAg, antibody to HBsAg and total antibody to hepatitis B core antigen together.
  • Screen every pregnant patient during each pregnancy, preferably early, regardless of vaccination or prior testing; a positive HBsAg result triggers time-critical maternal and infant prevention planning.
  • Offer testing to anyone who requests it and repeat risk-based testing while exposures persist, avoiding stigmatizing disclosure requirements that can block access.
  • Interpret the three markers as a pattern to distinguish current infection, resolved infection, vaccine immunity, susceptibility and isolated core antibody rather than labeling a patient from one result.
sources for this section:CDC HBV 2023

Practical clinical workflow

1
Review prior vaccination, country of birth, household or sexual exposure, injection use, incarceration, dialysis, HIV or HCV, immunosuppression, pregnancy and unexplained aminotransferase elevation.
2
Order the CDC triple panel for initial adult screening, then confirm unexpected or reactive results and add IgM anti-HBc, HBV DNA, alanine aminotransferase and other staging tests when the clinical question requires them.
3
Link current infection to a clinician experienced in HBV for phase assessment, fibrosis evaluation, treatment eligibility and liver-cancer surveillance; counsel on alcohol, transmission and blood donation.
4
Test household, sexual and needle-sharing contacts and vaccinate susceptible people without delaying the index patient鈥檚 care; document immunity and future reactivation risk clearly.
sources for this section:CDC HBV 2023

Safety boundaries and escalation

  • Jaundice, coagulopathy, encephalopathy, severe vomiting or rapidly worsening aminotransferases requires urgent assessment for acute or acute-on-chronic liver failure.
  • An HBsAg-positive pregnancy requires HBV DNA assessment and coordinated obstetric, hepatology and pediatric planning so newborn prophylaxis is delivered on time.
  • Resolved infection or isolated core antibody can reactivate during B-cell-depleting therapy, transplantation or other immunosuppression; assess reactivation prevention before treatment begins.
  • Do not postpone hepatitis B vaccination while waiting for screening results when follow-up is uncertain and vaccination is indicated; drawing blood before the first dose can preserve interpretability.
sources for this section:CDC HBV 2023

Localization

The United States moved to universal adult triple-panel screening in 2023 and has separate ACIP vaccination policy. State reporting, perinatal prevention programs, refugee-health systems and payer coverage affect implementation but not the need to link a positive patient safely to care.
sources for this section:CDC HBV 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionScreening and Testing for Hepatitis B Virus Infection: CDC Recommendations鈥擴nited States, 2023MMWR 72(1); DOI 10.15585/mmwr.rr7201a1 路 published 2023-03-10 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.